A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations

Trial Profile

A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ReTHINK
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 19 Jul 2017 This trial was completed in Austria, according to European Clinical Trials Database record.
    • 07 Jul 2017 This trial was completed in Belgium, according to European Clinical Trials Database record.
    • 26 May 2017 Planned primary completion date changed from 24 Mar 2021 to 15 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top